Rapamycin effects on mTOR signaling in benign, premalignant and malignant human breast epithelial cells

Anticancer Research

Volumn 29, Issue 4, 2009, Pages 1143-1150

  Kim, S O Hee ^a,b   Zukowski, Kim ^a   Novak, Raymond F ^a  

^a WAYNE STATE UNIVERSITY   (United States)

^b Gangneung Wonju National University   (South Korea)

Author keywords

Biomarkers of resistance; Early events in breast tumorigenesis; Human breast epithelial cells; Human breast premalignant and tumor epithelial cells; mTOR phosphorylation; mTOR signaling; p70s6 and Rs6P; Rapamycin; STATEt3 phosphorylation

Indexed keywords

MAMMALIAN TARGET OF RAPAMYCIN; RAPAMYCIN; STAT3 PROTEIN;

ARTICLE; BREAST CANCER; BREAST EPITHELIUM; CANCER PREVENTION; CANCER RECURRENCE; CANCER THERAPY; CELL CYCLE; CELL LINEAGE; CELL PROLIFERATION; CONTROLLED STUDY; DRUG EFFECT; DRUG INHIBITION; HUMAN; HUMAN CELL; PHOSPHORYLATION; PRIORITY JOURNAL; TUMOR CELL;

ANTIBIOTICS, ANTINEOPLASTIC; BREAST; BREAST NEOPLASMS; CELL CYCLE; CELL PROLIFERATION; CELLS, CULTURED; FLOW CYTOMETRY; HUMANS; IMMUNOBLOTTING; PHOSPHORYLATION; PRECANCEROUS CONDITIONS; PROTEIN KINASES; PROTO-ONCOGENE PROTEINS C-AKT; RIBOSOMAL PROTEIN S6 KINASES, 70-KDA; SIGNAL TRANSDUCTION; SIROLIMUS; STAT1 TRANSCRIPTION FACTOR;

EID: 64949114063     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (21)

1. Hidalgo M and Rowinsky EK: The rapamycin-sensitive signal transduction pathway as a target for cancer therapy. Oncogene 19: 6680-6686, 2000.
2. Oshiro N, Yoshino K, Hidayat S, Tokunaga C, Hara K, Eguchi S, Avruch J and Yonezawa K: Dissociation of raptor from mTOR is a mechanism of rapamycin-induced inhibition of mTOR function. Genes Cells 9: 359-366, 2004.
3. Mita MM, Mita A and Rowinsky EK: Mammalian target of rapamycin: a new molecular target for breast cancer. Clin Breast Cancer 4: 126-137,2003.
4. Dufner A, Andjelkovic M, Burgering BM, Hemmings BA and Thomas G: Protein kinase B localization and activation differentially affect S6 kinase 1 activity and eukaryotic translation initiation factor 4E-binding protein 1 phosphorylation. Mol Cell Biol 19: 4525-4534, 1999.
5. Jefferies HB, Fumagalli S, Dennis PB, Reinhard C, Pearson RB and Thomas G: Rapamycin suppresses 5'TOP mRNA translation through inhibition of p70s6k. EMBO J 16: 3693- 3704,1997.
6. Yokogami K, Wakisaka S, Avruch J and Reeves SA: Serine phosphorylation and maximal activation of STAT3 during CNTF signaling is mediated by the rapamycin target mTOR. Curr Biol 10: 47-50, 2000.
7. Clevenger CV: Roles and regulation of STAT family transcription factors in human breast cancer. Am J Pathol 165: 1449-1460,2004.
8. Jemal A, Tiwari RC, Murray T, Ghafoor A, Samuels A, Ward E, Feuer EJ and Thun MJ: Cancer statistics. CA Cancer J Clin 54: 8-29, 2004.
9. Dawson PJ, Wolman SR, Tait L, Heppner GH and Miller FR: MCF10AT: a model for the evolution of cancer from proliferative breast disease. Am J Pathol 148: 313-319, 1996.
10. Starcevic SL, Elferink C and Novak RF: Progressive resistance to apoptosis in a cell lineage model of human proliferative breast disease. J Natl Cancer Institute 93: 776-782, 2001.
11. Starcevic SL, Diotte NM, Zukowski KL, Cameron MJ and Novak RF: Oxidative DNA damage and repair in a cell lineage model of human proliferative breast disease (PBD). Toxicol Sci 75: 74-81,2003.
12. Soule HD, Maloney TM, Wolman SR, Peterson WD, Brenz R, McGrath CM, Russo J, Pauley RJ, Jones RF and Brooks SC: Isolation and characterization of a spontaneously immortalized human breast epithelial cell line, MCF-10. Cancer Res 50: 6075- 6086,1990.
13. Russo J, Tait L and Russo IH: Morphological expression of cell transformation induced c-Ha-ras oncogene in human breast epithelial cells. J Cell Sci 99: 453-463, 1991.
14. Miller FR, Soule HD, Tait L, Pauley RJ, Wolman SR, Dawson PJ and Heppner GH: Xenograft model of progressive human proliferative breast disease. J Natl Cancer Inst 85: 1725-1732, 1993.
15. Santner SJ, Dawson PJ, Tait L, Soule HD, Eliason J, Mohamed AN, Wolman SR, Heppner GH and Miller F: Malignant MCF10CA1 cell lines derived from premalignant human breast epithelial MCF10AT cells. Breast Cancer Res Treat 65: 101-110, 2001.
16. Noh WC, Mondesire WH, Peng J, Jian W, Zhang H, Dong J, Mills GB, Hung MC and Meric-Bernstam F: Determinants of rapamycin sensitivity in breast cancer cells. Clin Cancer Res 10: 1013-1023,2004.
17. Dilling MB, Germain GS, Dudkin L, Jayaraman AL, Zhang X, Harwood FC and Houghton PJ: 4E-binding proteins, the suppressors of eukaryotic initiation factor 4E, are down-regulated in cells with acquired or intrinsic resistance to rapamycin. J Biol Chem 277: 13907-13917, 2002.
18. Knudsen ES and Wang JY: Dual mechanisms for the inhibition of E2F binding to RB by cyclin-dependent kinase-mediated RB phosphorylation. Mol Cell Biol 17: 5771-5783, 1997.
19. Sun SY, Rosenberg LM, Wang X, Zhou Z, Yue P, Fu H and Khuri FR: Activation of Akt and eIF4E survival pathways by rapamycin-mediated mammalian target of rapamycin inhibition. Cancer Res 65: 7052-7058, 2005.
20. O'Reilly KE, Rojo F, She QB, Solit D, Mills GB, Smith D, Lane H, Hofmann F, Hicklin DJ, Ludwig DL, Baselga J and Rosen N: mTOR inhibition induces upstream receptor tyrosine kinase signaling and activates Akt. Cancer Res 66: 1500-1508, 2006.
21. Meric F, Hung MC, Hortobagyi GN and Hunt KK: HER2/neu in the management of invasive breast cancer. J Am Coll Surg 194: 488-501,2002.